DarioHealth (DRIO) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
12 Nov, 2026Platform and market opportunity
Integrated digital platform addresses 6+ conditions across cardiometabolic, behavioral, and musculoskeletal care; bundled pricing is $74 per engaged member per month.
Stated market opportunity exceeds $250B in serviceable addressable market and $1T in total addressable market.
13B+ proprietary data points support clinical services, member navigation, and platform development.
90% of U.S. healthcare spending is attributed to chronic disease; 3 in 4 U.S. adults have a chronic disease and 5 in 10 have two or more.
Care model and outcomes
Member support combines connected devices, self-guided programs, AI-powered coaching, community, education, and access to clinical services.
Reported outcomes include 1.4–2.3-point A1C reductions, 13 mmHg systolic blood pressure reduction for 66%+ of qualifying members, and 50% pain reduction.
Third-party-validated studies cited $5,077 in medical cost savings per user; App Store rating was 4.8/5 across ~25,000 reviews.
Announced expansion into provider-backed care adds clinician escalation, prescribing, diagnostic testing, and a 50-state provider network.
AI and operating model
DarioIQ personalizes content, timing, and outreach using member data; reported 40% higher engagement and 20% better retention versus a control group.
AI is used across product, data, clinical operations, support, finance, R&D, member engagement, and client reporting to improve efficiency.
The platform combines FDA-cleared connected devices, longitudinal clinical data, a proprietary AI engine, and behavior-triggered interventions.
Latest events from DarioHealth
- Multi-condition care and provider expansion underpin $13.1M in ARR opportunities.DRIO
Investor presentation - Q3 revenue rose 6.1%; ARR supports 2027 growth expectations amid funding risks.DRIO
Q3 2026 - Gross margin rose to 62% and net loss improved 39% as ARR, cash, and commercial wins increased.DRIO
Q2 2026 - AI-driven multi-condition platform delivers clinical results, high retention, and rapid growth.DRIO
Corporate presentation - Q1 2026 revenue rose to $5.6M, costs fell, but liquidity concerns remain despite strong pipeline.DRIO
Q1 2026 - Multi-condition digital health platform delivers strong growth, clinical outcomes, and high retention.DRIO
Corporate presentation - AI-driven, multi-condition platform achieves clinical validation, strong growth, and high client retention.DRIO
Corporate presentation - Registering up to $100M in securities to support growth and innovation in digital health.DRIO
Registration filing - Record new business and margin gains set the stage for accelerated, ARR-driven growth by 2027.DRIO
Q4 2025